PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.51%
Revenue growth similar to CRON.TO's 9.78%. Walter Schloss would see if both companies share industry tailwinds.
7.27%
Gross profit growth under 50% of CRON.TO's 40.46%. Michael Burry would be concerned about a severe competitive disadvantage.
-21.53%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-21.53%
Negative operating income growth while CRON.TO is at 2.43%. Joel Greenblatt would press for urgent turnaround measures.
12.27%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
16.96%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
16.96%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
5.73%
Share count expansion well above CRON.TO's 0.19%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.73%
Diluted share count expanding well above CRON.TO's 0.19%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-91.95%
Negative OCF growth while CRON.TO is at 179.13%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-81.39%
Negative FCF growth while CRON.TO is at 119.72%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
233.46%
5Y revenue/share CAGR 1.25-1.5x CRON.TO's 211.78%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
-47.78%
Negative 3Y CAGR while CRON.TO stands at 72.86%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-1691.31%
Negative 10Y OCF/share CAGR while CRON.TO stands at 444.13%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-637.63%
Negative 5Y OCF/share CAGR while CRON.TO is at 103.49%. Joel Greenblatt would question the firm’s operational model or cost structure.
-556.05%
Negative 3Y OCF/share CAGR while CRON.TO stands at 104.22%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-5853.83%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-133.36%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
82.42%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
5683.87%
Below 50% of CRON.TO's 16399.29%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-29.32%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-23.00%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.38%
AR growth is negative/stable vs. CRON.TO's 61.09%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
8.89%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.63%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.64%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.92%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-29.11%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
7.54%
SG&A declining or stable vs. CRON.TO's 18.94%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.